All News
Filter News
Found 808,963 articles
-
New York Patients Are Being Forced Off Prescribed Medications During the Plan Year, Providing A Need for New Legislation to Fix the Problem
5/1/2018
Global Healthy Living Foundation (GHLF) released results of a survey showing that a majority of those in New York living with chronic health conditions have experienced “non-medical switching”—insurance coverage reductions which pressure patients to switch their prescription medications.
-
Eli Lilly and Company announced that Leena Gandhi will lead its immuno-oncology medical development program.
-
Allergan Chief Executive Officer Brent Saunders delivered a rosy review of the first quarter for 2018, including a 3 percent growth in revenue to $3.67 billion over the past three months. However, investors are not terribly pleased and shares have fallen nearly 4 percent this morning.
-
Proniras Corporation launched from Accelerator Life Science Partners to treat nerve agents. The company recently received a contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) for $89.5 million.
-
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
-
Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 million in contingent consideration.
-
The U.S. Food and Drug Administration (FDA) cleared Haifa, Israel-based Pluristem Therapeutics’ Investigational New Drug (IND) application for PLX-R18 to treat acute radiation syndrome (ARS).
-
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
-
San Diego-based Synthorx announced it had completed a Series C financing round worth $63 million.The monies raised will be used to advance its pipeline of Synthorin cytokines.
-
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
-
Merck appears to be on the way to securing an additional approval for Keytruda, its blockbuster checkpoint inhibitor. The company is seeking new regulatory approval for Keytruda, an anti-PD-1 therapy, in combination with Eli Lilly’s Alimta and platinum chemotherapy as a first-line lung cancer tre...
-
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products
4/30/2018
4D Molecular Therapeutics today announced the expansion of its 2016 research agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. into a broad long-term partnership to develop and commercialize multiple ophthalmology products.
-
Predicine Launches PredicineATLAS, a 600-gene Blood-based TMB Panel to Accelerate Immuno-oncology Clinical Trials
4/30/2018
The panel is expected to be one of the industry's largest liquid biopsy panels, covering gene content of major commercially available TMB panels in the immunotherapy space.
-
Tandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump
4/30/2018
The Company plans to begin commercial sales of the pump in select international markets beginning in the second half of 2018.
-
John C. Lechleiter appointed to Indiana Biosciences Research Institute board of directors
4/30/2018
The Indiana Biosciences Research Institute (IBRI) announces former Eli Lilly and Company chairman, president and CEO John C. Lechleiter, Ph.D., has joined its board of directors. Dr. Lechleiter retired from Lilly in 2016 and served as chairman of the board of directors from January 2009 to May 2017. He joined Lilly in 1979 as a senior organic chemist, working his way from the lab to global leadership.
-
Body Vision Medical Receives FDA Clearance for the LungVision Tool, Part of the LungVision Platform Revolutionizing the Areas of Lung Cancer Diagnostics and Treatment
4/30/2018
The clearance paved the way for accelerating commercialization efforts.
-
Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study
4/30/2018
Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting
-
Stockholders Approve Genoptix Acquisition of Rosetta Genomics
4/30/2018
Genoptix will immediately begin Marketing, Selling and Distributing the complete Rosetta Genomics Portfolio
-
Sight Sciences Initiates U.S. Pivotal Trial of the TearCare® System for the Treatment of Dry Eye Disease
4/30/2018
Trial to evaluate the safety and effectiveness of the TearCare® System in patients with dry eye disease.
-
New Phase 4 OSCAR Trial Data Showed that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Decreased Acne Lesions Therefore Reducing the Risk of Scars in Moderate-to-Severe Acne Patients
4/30/2018
Data Reinforces Importance of Scar Prevention as an Important Goal of Acne Treatment